Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Lilly

Status

Conditions: Metastatic Breast Cancer

Treatments: Drug: Abemaciclib

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT03763604

17088

I3Y-MC-Y001 (Other Identifier)

Details and patient eligibility

About

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients with hormone receptor positive metastatic breast cancer for whom there is reasonable expectation that abemaciclib may provide clinical benefit and who are suitable to receive abemaciclib.